Filing Flows › Repligen (RGEN) › Q2 2025
Repligen (RGEN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Repligen (RGEN) reported revenue of $182M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +8% from the quarter before. Operating margin was 7.6%, net earnings $14.9M (8.2% of revenue).
Repligen, Q2 2025: revenue $182M (+15% year over year), operating margin 7.6%, net earnings $14.9M, operating cash flow $28.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $182M | +8% | +15% |
| Operating profit | $13.9M | +111% | +154% |
| Net earnings | $14.9M | +155% | +160% |
| Operating cash flow | $28.6M | +91% | -32% |
| Free cash flow | $21.5M | +88% | -42% |
What changed
Revenue was $182.4M in Q2 2025, up 15% year over year and up 8% from the previous quarter. Product was the largest line at 100% of revenue. Product added $23.5M year over year (up 15%), 100% of the total change.
Operating profit was $13.9M, a 7.6% margin (up 4.2 points year over year). Of the extra revenue versus a year earlier, 36% reached operating profit, above the 3% margin then. Total costs grew 10% against revenue growth of 15%. Net earnings were $14.9M, up 160% year over year. The effective tax rate was 18.4%. Non-operating items added $4.3M, 24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $28.6M (down 32% year over year), 192% of net earnings. Non-cash charges added back $20.1M of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items used $14.7M. Capital expenditures of $7.1M left free cash flow of $21.5M.
Questions
What was Repligen's revenue in the second quarter 2025?
Repligen (RGEN) reported revenue of $182M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +8% from the quarter before.
Was Repligen profitable in the second quarter 2025?
Operating profit was $13.9M (7.6% of revenue) and net earnings $14.9M.
Source: Repligen 10-Q on SEC EDGAR.